It is important to note that oncogenic activity of HIF2α has only been clearly demonstrated in a limited number of tumor types, most notably in clear cell renal cell carcinoma (ccRCC) and paragangliomas (PPGL). Here, EPAS1 is linked to nonpapillary renal cell carcinoma.